| Clinical data | |
|---|---|
| Other names | Progesterone conjugate |
| Drug class | Progestogen; Neurosteroid |
| Identifiers | |
| CAS Number | |
VOLT-02 is a water-soluble conjugate of progesterone and a neurosteroid which is under development by Levolta Pharmaceuticals (formerly Voltarra Pharmaceuticals) for the treatment of traumatic brain injury, gynecological disorders, and menstrual disorders. [1] As of March 2017, it is in phase II clinical trials for these indications. [1] The chemical structure of VOLT-02 does not appear to have been released yet. [1]